• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Histone deacetylase 5 is a phosphorylation substrate of protein kinase D in osteoclasts.组蛋白去乙酰化酶5是破骨细胞中蛋白激酶D的磷酸化底物。
Bone. 2022 Jun;159:116393. doi: 10.1016/j.bone.2022.116393. Epub 2022 Mar 19.
2
Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling.蛋白激酶 D1 介导 IIa 类组蛋白去乙酰化酶在肠道上皮细胞中的磷酸化和核外排:在有丝分裂信号中的作用。
Am J Physiol Cell Physiol. 2014 May 15;306(10):C961-71. doi: 10.1152/ajpcell.00048.2014. Epub 2014 Mar 19.
3
Converse role of class I and class IIa HDACs in the progression of atrial fibrillation.I 类和 IIa 类组蛋白去乙酰化酶在心房颤动进展中的相反作用。
J Mol Cell Cardiol. 2018 Dec;125:39-49. doi: 10.1016/j.yjmcc.2018.09.010. Epub 2018 Oct 12.
4
Cyclic AMP represses pathological MEF2 activation by myocyte-specific hypo-phosphorylation of HDAC5.环磷酸腺苷通过组蛋白去乙酰化酶5的心肌细胞特异性低磷酸化来抑制病理性的肌细胞增强因子2激活。
J Mol Cell Cardiol. 2020 Aug;145:88-98. doi: 10.1016/j.yjmcc.2020.05.018. Epub 2020 May 30.
5
Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4.组蛋白去乙酰化酶5通过与组蛋白去乙酰化酶4寡聚化而获得钙/钙调蛋白依赖性激酶II反应性。
Mol Cell Biol. 2008 May;28(10):3437-45. doi: 10.1128/MCB.01611-07. Epub 2008 Mar 10.
6
Deletion of histone deacetylase 7 in osteoclasts decreases bone mass in mice by interactions with MITF.破骨细胞中组蛋白去乙酰化酶7的缺失通过与小眼畸形相关转录因子相互作用降低小鼠骨量。
PLoS One. 2015 Apr 15;10(4):e0123843. doi: 10.1371/journal.pone.0123843. eCollection 2015.
7
Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation.组蛋白去乙酰化酶 5 通过必需核定位信号磷酸化进行核输入。
Mol Cell Proteomics. 2011 Feb;10(2):M110.004317. doi: 10.1074/mcp.M110.004317. Epub 2010 Nov 16.
8
The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.CRT0066101作为三阴性乳腺癌有效治疗药物的作用及机制
Cell Physiol Biochem. 2019;52(3):382-396. doi: 10.33594/000000027. Epub 2019 Mar 8.
9
Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.I 类和 II 类组蛋白去乙酰化酶抑制剂可抑制体外人破骨细胞。
J Cell Physiol. 2011 Dec;226(12):3233-41. doi: 10.1002/jcp.22684.
10
Identification of NuRSERY, a new functional HDAC complex composed by HDAC5, GATA1, EKLF and pERK present in human erythroid cells.鉴定出NuRSERY,一种由存在于人类红细胞中的HDAC5、GATA1、EKLF和pERK组成的新型功能性组蛋白去乙酰化酶复合物。
Int J Biochem Cell Biol. 2014 May;50:112-22. doi: 10.1016/j.biocel.2014.02.019. Epub 2014 Mar 1.

本文引用的文献

1
Multifaceted Functions of Protein Kinase D in Pathological Processes and Human Diseases.蛋白激酶D在病理过程和人类疾病中的多方面功能
Biomolecules. 2021 Mar 23;11(3):483. doi: 10.3390/biom11030483.
2
Hdac3 regulates bone modeling by suppressing osteoclast responsiveness to RANKL.Hdac3 通过抑制破骨细胞对 RANKL 的反应来调节骨建模。
J Biol Chem. 2020 Dec 18;295(51):17713-17723. doi: 10.1074/jbc.RA120.013573.
3
Hdac3 deletion in myeloid progenitor cells enhances bone healing in females and limits osteoclast fusion via Pmepa1.在髓系祖细胞中删除 Hdac3 通过 Pmepa1 增强女性骨愈合并限制破骨细胞融合。
Sci Rep. 2020 Dec 11;10(1):21804. doi: 10.1038/s41598-020-78364-5.
4
PTHrP targets salt-inducible kinases, HDAC4 and HDAC5, to repress chondrocyte hypertrophy in the growth plate.甲状旁腺激素相关蛋白靶向盐诱导激酶、HDAC4 和 HDAC5,抑制生长板中的软骨细胞肥大。
Bone. 2021 Jan;142:115709. doi: 10.1016/j.bone.2020.115709. Epub 2020 Oct 24.
5
Regulation of histone deacetylase activities and functions by phosphorylation and its physiological relevance.组蛋白去乙酰化酶活性和功能的磷酸化调节及其生理相关性。
Cell Mol Life Sci. 2021 Jan;78(2):427-445. doi: 10.1007/s00018-020-03599-4. Epub 2020 Jul 18.
6
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.三十年 HDAC 抑制剂:2020 年的新视角和新认识。
J Med Chem. 2020 Nov 12;63(21):12460-12484. doi: 10.1021/acs.jmedchem.0c00830. Epub 2020 Jul 16.
7
Loss of myocyte enhancer factor 2 expression in osteoclasts leads to opposing skeletal phenotypes.破骨细胞中肌细胞增强因子 2 表达的缺失导致相反的骨骼表型。
Bone. 2020 Sep;138:115466. doi: 10.1016/j.bone.2020.115466. Epub 2020 Jun 6.
8
Regulation of Osteoclast Differentiation at Multiple Stages by Protein Kinase D Family Kinases.蛋白激酶 D 家族激酶在破骨细胞分化的多个阶段的调节作用。
Int J Mol Sci. 2020 Feb 5;21(3):1056. doi: 10.3390/ijms21031056.
9
Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro.组蛋白去乙酰化酶 1 和 2 的抑制作用可抑制细胞因子的产生和体外破骨细胞的骨吸收。
J Cell Biochem. 2020 Jan;121(1):244-258. doi: 10.1002/jcb.29137. Epub 2019 Jun 21.
10
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review.基于分子的骨质疏松治疗策略:文献综述。
Int J Mol Sci. 2019 May 24;20(10):2557. doi: 10.3390/ijms20102557.

组蛋白去乙酰化酶5是破骨细胞中蛋白激酶D的磷酸化底物。

Histone deacetylase 5 is a phosphorylation substrate of protein kinase D in osteoclasts.

作者信息

Meyers Carina Mello Guimaraes, Burciaga Samuel D, Faulkner Bora, Kazemi Parandis, Cohn Jacob M, Mansky Kim C, Jensen Eric D

机构信息

Department of Diagnostic & Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN 55455, USA.

Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA.

出版信息

Bone. 2022 Jun;159:116393. doi: 10.1016/j.bone.2022.116393. Epub 2022 Mar 19.

DOI:10.1016/j.bone.2022.116393
PMID:35318161
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9035101/
Abstract

Protein kinase D (PRKD) family kinases are required for formation and function of osteoclasts. However, the substrates of PRKD in osteoclasts are unknown. To identify PRKD-dependent protein phosphorylation in osteoclasts, we performed a quantitative LC-MS/MS phosphoproteomics screen for proteins showing differential phosphorylation in osteoclasts after treatment with the PRKD inhibitor CRT0066101. We identified 757 phosphopeptides showing significant changes following PRKD inhibition. Among the changes, we found a group of 13 proteins showing decreased phosphorylation at PRKD consensus phosphorylation motifs. This group includes histone deacetylase 5 (HDAC5), which is a previously validated PRKD target. Considering this known interaction, work suggesting HDACs may be important regulators of osteoclasts, and studies suggesting potential functional redundancy between HDACs, we further investigated the relationship between PRKD and class IIa HDACs in osteoclasts. We confirmed that CRT0066101 inhibits phosphorylation of endogenous HDAC5 and to a lesser extent HDAC4, whereas HDAC7 phosphorylation was not affected. Osteoclast cultures from Hdac5 global knockout mice displayed impaired differentiation and reduced ability to resorb bone, while conditional knockout of Hdac4 in osteoclasts showed no phenotype in vitro or in vivo. The inhibitory effect of CRT0066101 was reduced in Hdac5 KO osteoclasts. Together these data indicate that the PRKD/HDAC5 axis contributes to osteoclast formation in vitro and suggest that this pathway may contribute to regulation of skeletal dynamics in vivo.

摘要

蛋白激酶D(PRKD)家族激酶是破骨细胞形成和功能所必需的。然而,破骨细胞中PRKD的底物尚不清楚。为了鉴定破骨细胞中PRKD依赖性蛋白磷酸化,我们进行了定量液相色谱-串联质谱磷酸化蛋白质组学筛选,以寻找在用PRKD抑制剂CRT0066101处理后的破骨细胞中显示出磷酸化差异的蛋白质。我们鉴定出757个磷酸肽在PRKD抑制后显示出显著变化。在这些变化中,我们发现一组13种蛋白质在PRKD共有磷酸化基序处的磷酸化减少。该组包括组蛋白去乙酰化酶5(HDAC5),它是先前已验证的PRKD靶标。考虑到这种已知的相互作用、提示HDACs可能是破骨细胞重要调节因子的研究以及提示HDACs之间存在潜在功能冗余的研究,我们进一步研究了破骨细胞中PRKD与IIa类HDACs之间的关系。我们证实CRT0066101抑制内源性HDAC5的磷酸化,对HDAC4的抑制作用较小,而HDAC7的磷酸化不受影响。来自Hdac5基因敲除小鼠的破骨细胞培养物显示分化受损且骨吸收能力降低,而破骨细胞中Hdac4的条件性敲除在体外或体内均未显示出表型。CRT0066101对Hdac5基因敲除破骨细胞的抑制作用减弱。这些数据共同表明PRKD/HDAC5轴在体外有助于破骨细胞形成,并提示该途径可能在体内对骨骼动力学调节起作用。